key: cord-0949098-qifrat4d
authors: Cava, Edda; Neri, Barbara; Carbonelli, Maria Grazia; Riso, Sergio; Carbone, Salvatore
title: Obesity pandemic during COVID-19 outbreak: Narrative review and future considerations
date: 2021-03-02
journal: Clin Nutr
DOI: 10.1016/j.clnu.2021.02.038
sha: ea61ad78a3fedb3a661e44084209717766340844
doc_id: 949098
cord_uid: qifrat4d

The high prevalence of obesity and obesity-related comorbidities has reached pandemic proportions, particularly in Western countries. Obesity increases the risk to develop several chronic noncommunicable disease, ultimately contributing to reduced survival. Recently, obesity has been recognized as major risk factor for coronavirus disease-19 (COVID-19)-related prognosis, contributing to worse outcomes in those with established COVID-19. Particularly, obesity has been associated with higher hospitalization rates in acute or intensive care and greater risk for invasive mechanical ventilation than lean people. Obesity is characterized by metabolic impairments and chronic low-grade systemic inflammation that causes a pro-inflammatory microenvironment, further aggravating the cytokine production and risk of cytokine storm response during Sars-Cov2 sepsis or other secondary infections. Moreover, the metabolic dysregulations are closely related to an impaired immune system and altered response to viral infection that can ultimately lead to a greater susceptibility to infections, longer viral shedding and greater duration of illness and severity of the disease. In individuals with obesity, maintaining a healthy diet, remaining physically active and reducing sedentary behaviors are particularly important during COVID-19-related quarantine to reduce metabolic and immune impairments. Moreover, such stategies are of utmost importance to reduce the risk for sarcopenia and sarcopenia obesity, and to prevent a reduction and potentially even increase cardiorespiratoty fitness, a well-known independent risk factor for cardiovascular and metabolic diseases and recently found to be a risk factor also for hospitalizations secondary to COVID-19. Such lifestyle strategies may ultimately reduce morbility and mortality in patients with infectious disease, especially in those with concomitant obesity. The aim of this review is to discuss how obesity might increase the risk of COVID-19 and potentially affect its prognosis once COVID-19 is diagnosed. We therefore advocate for implementation of strategies aimed at preventing obesity in the first place, but also to minimize the metabolic anomalies that may lead to a compromized immune response and chronic low-grade systemic inflammation, especially in patients with COVID-19.

within those aged 50-64 years obesity was even more prevalent than hypertension and DM (15). 126

In figure J o u r n a l P r e -p r o o f in more than 5279 patients, confirm that age >44 years and morbid obesity (BMI ≥40 Kg/m 2 ) 140 were strong predictors for hospitalization. Specifically, in those 75 years or older, odds ratio 141 (OR) for hospitalization was 37.9 (95% CI, 26.1-56); age 65-74 years OR was 8.7 (95% CI, 8.7-142 11), and BMI ≥40 kg/m 2 OR was 2.5 (95% CI, 1.8-3.4) (18). 143

Another report by Lighter et al. highlights the major impact of obesity in the age group 144 younger than 60 years, in a cohort from NYC positive for COVID-19, that was fairly 145 representative of USA population (19), with 21% of the total cohort having a BMI 30-34 kg/m 2 , 146 and 16% BMI ≥35 kg/m 2 . Patients <60 years of age and with a BMI between 30-34 kg/m 2 were 147 two times more likely to be admitted to acute or critical care, while patients with a BMI ≥35 148

Kg/m 2 and aged <60 years were 2.2 times more likely to be admitted to acute care and 3 times to 149 ICU, compared to individuals without obesity. Subjects <60 years of age in the general 150 population without obesity were believed to be a lower risk group for COVID-19 with a more 151 favorable prognosis, however, especially in Western countries characterized by the high 152 prevalence of obesity, Sars-Cov-2 is spreading rapidly among the population. Obesity has been, 153 in fact, confirmed as an independent risk factor even in younger individuals in other reports: one 154 from an American cohort from California in which a higher level of care was required by 155 patients with obesity (OR 2.0, P= 0.021) (4); and one in which BMI >30 was significantly 156 associated with higher risk for mortality, IMV and hospital admission (OR 95%CI of 6.29, 6.01, admitted for non-SARS-CoV-2 severe acute respiratory syndrome in the previous year (20). 163 Noteworthy, another French study reports a lower prevalence of obesity in ICU and less people 164 requiring IMV, explaining that this difference can be due to a lower prevalence of obesity in that 165 specific area, which was lower than a half compared to the population of the previously 166 discussed study. Even if the overall prevalence of obesity was lower, however, in those with 167 severe obesity the risk for IMV remained significantly greater than in the leaner counterparts 168 and it could potentially also explain, at least in part, the increased risk for severe complications 244 once COVID-19 is diagnosed (25) (26) . 245 BMI positively correlates with infectious virus shedding in aerosol of cases affected by 246 influenza virus, and vaccination coverage is less efficient in individuals with obesity (27) . 247

Moreover, patients with obesity show a more prolonged duration of illness as well as a greater 248 risk for severe influenza-like illness and higher respiratory mortality during previous pandemic 249 of viral infections, consistently with recent data on COVID-19-related mortality. This was 250 confirmed by a large body of evidence, which has reported an impaired immune response to 251 influenza or influenza-like viruses in obesity. Notably, subjects with obesity shed influenza A 252 virus for a longer period of time than subjects without obesity, having a viral shedding 42% 253 longer when symptomatic and up to 104% longer in asymptomatic or pauci-symptomatic 254 subjects (28). Therefore, obesity plays a crucial role in viral transmission, significantly 255 increasing the chance to spread influenza and influenza-like diseases in countries where the 256 prevalence of obesity is high. 257 hyperinflammatory state in obesity that could explain these data (29-30). Although the lockdown is the principal strategy to contain the virus spread, it can 302 promote sedentary behaviors, reducing regular PA and energy expenditure and increasing the worse outcomes in COVID-19 infections (13). Therefore, it is strongly recommended to maintain 305 appropriate level of PA, even at home during quarantine also to counteract the loss of muscle 306 mass and muscle functionality and therefore the risk for sarcopenia, and to maintain adequate 307 immune system functions during such a current difficult period (43-44). It is possible to improve 308 cardiorespiratory fitness at home by performing safe, simple, and easy exercises, as stretching 309 and strengthening exercises, activities for balance and control, or a combination of them (e.g. 

In the age range 18-64 years old obesity was the most prevalent comorbidity

Prevalence of obesity and severe obesity 422 among adults: United States

Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions 425

Among Patients with Coronavirus Disease 2019 -United States

DOI

Epidemiology, clinical course, and 429 outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort 430 study

Pre-existing traits associated with Covid-19 illness 432 severity

Young Adults with COVID-19

Dying in Relation to COVID-19 in Italy

Hospitalization Rates and Characteristics of Patients 468 Hospitalized with Laboratory-Confirmed Coronavirus Disease

COVID-NET: COVID-19-Associated Hospitalization Surveillance Network

and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the

Factors associated with hospital admission and 479 critical illness among 5279 people with coronavirus disease 2019 in New York City: 480 prospective cohort study

Obesity as a risk factor for greater severity of COVID-490 19 in patients with metabolic associated fatty liver disease

Cardiovascular Disease Patients Infected by 2019-nCoV

Regulation of angiotensin 498 converting enzyme 2 (ACE2) in obesity: implications for COVID-19

COVID-19 and Angiotensin-Converting Enzyme Inhibitors and 501

Angiotensin Receptor Blockers: What Is the Evidence?

Impact of Obesity on Influenza A Virus Pathogenesis